Interactions Between the Complement System and Fcγ Receptors

Antibody Fc: Linking Adaptive and Innate Immunity

Volumn , Issue , 2013, Pages 49-74

  Lindorfer, Margaret A ^a   Köhl, Jörg ^b,c   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Complement; Complement receptors; Fc receptors; HIV; Immune complexes; SLE

Indexed keywords

EID: 84896702806     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394802-1.00003-0     Document Type: Chapter

References (152)

1. Walport MJ Complement. N Engl J Med 2001, 344:1058-1066.
2. Degn SE, Thiel S, Jensenius JC New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007, 212:301-311.
3. Gros P, Milder FJ, Janssen BJ Complement driven by conformational changes. Nat Rev Immunol 2008, 8:48-58.
4. Ricklin D, Hajishengallis G, Yang K, Lambris JD Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
5. Wagner E, Frank MM Therapeutic potential of complement modulation. Nat Rev Drug Disc 2010, 9:43-56.
6. Dunkelberger JR, Song WC Complement and its role in innate and adaptive immune responses. Cell Res 2010, 20:34-50.
7. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011, 17:317-329.
8. Fries LF, Siwik SA, Malbran A, Frank MM Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leukocytes. Immunology 1987, 62:45-51.
9. Brown EJ, Joiner KA, Cole RM, Berger M Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun 1983, 39:403-409.
10. Huang ZY, Hunter S, Chien P, et al. Interaction of two phagocytic host defense systems: Fcγ receptors and complement receptor 3. J Biol Chem 2011, 286:160-168.
11. Parker C Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009, 373:759-767.
12. Botto M, Kirschfink M, Macor P, et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol 2009, 46:2774-2783.
13. Atkinson JP C5a and Fcγ receptors: a mutual admiration society. J Clin Invest 2006, 116:304-306.
14. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of Rituximab in vivo. J Immunol 2003, 171:1581-1587.
15. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non- Hodgkin's lymphomas. Blood 2003, 101:949-954.
16. Zent CS, Chen JB, Kurten RC, et al. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004, 28:495-507.
17. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood 2004, 104:1793-1800.
18. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172:3280-3288.
19. Berdeja JG, Hess A, Lucas DM, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 2007, 13:2392-2399.
20. de Haij S, Jansen JHM, Boross P, et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010, 70:3209-3217.
21. Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012, 188:3532-3541.
22. Ehlenberger AG, Nussenzweig V The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med 1977, 145:357-370.
23. Frank MM, Basta M, Fries LF The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992, 62:S82-S86.
24. Solomon S, Kassahn D, Illges H The role of the complement and the FcγR system in the pathogenesis of arthritis. Arthritis Res 2005, 7:129-135.
25. Schmidt RE, Gessner JE Fc receptors and their interaction with complement in autoimmunity. Immunol Lett 2005, 100:56-67.
26. Holers VM The spectrum of complement alternative pathway-mediated diseases. Immunol Rev 2008, 223:300-316.
27. Tsuboi N, Ernandez T, Li X, et al. Regulation of human neutrophil Fcγ receptor IIa by C5a receptor promotes inflammatory arthritis in mice. Arthritis Rheum 2011, 63:467-478.
28. 1 links FcγRIIB and Dectin-1 to block complement-mediated inflammation. Nat Med 2012, 18:1401-1406.
29. Nelson RA The immune-adherence phenomenon. An immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 1953, 118:733-737.
30. Nelson RA The immune-adherence phenomenon. A hypothetical role of erythrocytes in defense against bacteria and viruses. Proc Royal Soc Med 1955, 49:55-58.
31. Robineaux R, Pinet J An in vitro study of some mechanisms of antigen uptake by cells. Ciba foundation symposium on cellular aspects of immunity 1960, 5-43. Little, Brown, Boston, MA. G.E.W. Woldstenholme (Ed.).
32. Arnaout MA, Melamed J, Tack BF, Colten HR Characterization of the human complement (C3b) receptor with a fluid phase C3b dimer. J Immunol 1981, 127:1348-1354.
33. Ahearn JM, Fearon DT Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989, 46:183-217.
34. Lindorfer MA, Hahn CS, Foley PL, Taylor RP Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev 2001, 183:10-24.
35. Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983, 71:236-247.
36. Li J, Wang JP, Ghiran I, et al. Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun 2010, 78:3129-3135.
37. Hebert LA, Cosio FG The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int 1987, 31:877-885.
38. Schifferli JA, Taylor RP Physiological and pathological aspects of circulating immune complexes. Kidney Int 1989, 35:993-1003.
39. Medof ME, Iida K, Mold C, Nussenzweig V Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982, 156:1739-1754.
40. Nielsen CH, Matthiesen SH, Lyng I, Leslie RG The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes. Immunology 1997, 90:129-137.
41. Kimberly RP, Edberg JC, Merriam LT, et al. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J Clin Invest 1989, 84:962-970.
42. Edberg JC, Kimberly RP, Taylor RP Functional characterization of non-human primate erythrocyte immune adherence receptors: implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system. Eur J Immunol 1992, 22:1333-1339.
43. Fearon DT Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979, 76:5867-5871.
44. Fearon DT Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 1980, 152:20-30.
45. Miyakawa Y, Yamada A, Kosaka K, et al. Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet 1981, 2:493-497.
46. Iida K, Mornaghi R, Nussenzweig V Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 1982, 155:1427-1438.
47. Taylor RP, Horgan C, Buschbacher R, et al. Decreased complement mediated binding of antibody/3H-dsDNA immune complexes to the red blood cells of patients with systemic lupus erythematosus, rheumatoid arthritis, and hematologic malignancies. Arthritis Rheum 1983, 26:736-744.
48. Ross GD, Yount WJ, Walport MJ, et al. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985, 135:2005-2014.
49. Tausk FA, McCutchan A, Spechko P, Schreiber RD, Gigli I Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men: varying risk groups for acquired immune deficiency syndrome. J Clin Invest 1986, 78:977-982.
50. Ripoche J, Sim RB Loss of complement receptor type 1 (CR1) on ageing of erythrocytes: studies of proteolytic release of the receptor. Biochem J 1986, 235:815-821.
51. Pascual M, Danielsson C, Steiger G, Schifferli JA Proteolytic cleavage of CR1 on human erythrocytes in vivo: evidence for enhanced cleavage in AIDS. Eur J Immunol 1994, 24:702-708.
52. Sadallah S, Hess C, Miot S, et al. Elastase and metalloproteinase activities regulate soluble complement receptor 1 release. Eur J Immunol 1999, 29:3754-3761.
53. Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987, 1:89-94.
54. Currie MS, Vala M, Pisetsky DS, et al. Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. Blood 1990, 75:1699-1704.
55. Taylor RP, Sutherland WM, Martin EN, et al. Bispecific monoclonal antibody complexes bound to primate erythrocyte CR1 facilitate virus clearance in a monkey model. J Immunol 1997, 158:842-850.
56. Taylor RP, Martin EN, Reinagel ML, et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 1997, 159:4035-4044.
57. Craig ML, Reinagel ML, Martin EN, et al. Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen. Clin Immunol 1999, 92:170-180.
58. Joly E, Hudrisier D What is trogocytosis and what is its purpose?. Nat Immunol 2003, 4:815.
59. Hudrisier D, Aucher A, Puaux AL, Bordier C, Joly E Capture of target cell membrane components via trogocytosis is triggered by a selected set of surface molecules on T or B cells. J Immunol 2007, 178:3637-3647.
60. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell. J Immunol 2010, 184:1897-1908.
61. Zimring JC, Cadwell CM, Spitalnik SL Antigen loss from antibody-coated red blood cells. Transfusion Med Rev 2009, 23:189-204.
62. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-2609.
63. Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011, 187:3438-3447.
64. Wilson JG, Jack RM, Wong WW, Schur PH, Fearon DT Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus. J Clin Invest 1985, 76:182-190.
65. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
66. Henson SE, Smith D, Boackle SA, Holers VM, Karp DR Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J Immunol Methods 2001, 258:97-109.
67. Lindorfer MA, Jinivizian HB, Foley PL, et al. The B cell complement receptor 2 transfer reaction. J Immunol 2003, 170:3671-3678.
68. Holers VM, Kulik L Complement receptor 2, natural antibodies and innate immunity: inter-relationships in B cell selection and activation. Mol Immunol 2007, 44:64-72.
69. Whipple EC, Shanahan RS, Ditto AH, Taylor RP, Lindorfer MA Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. J Immunol 2004, 173:2297-2306.
70. Whipple EC, Ditto AH, Shanahan RS, et al. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol Immunol 2007, 44:377-388.
71. Westermann J, Pabst R Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system. Immunol Today 1990, 11:406-410.
72. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 2005, 102:15178-15183.
73. Brown JC, Harris G, Papamichail M, Sljivic VS, Holborow EJ The localization of aggregated human γ-globulin in the spleens of normal mice. Immunology 1973, 24:955-968.
74. Cinamon G, Zachariah MA, Lam OM, Foss FW, Cyster JG Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008, 9:54-62.
75. Gonzalez SF, Degn SE, Pitcher LA, et al. Trafficking of B cell antigen in lymph nodes. Ann Rev Immunol 2011, 29:215-233.
76. Humphrey JH, Grennan D, Sundaram V The origin of follicular dendritic cells in the mouse and the mechanism of trapping of immune complexes on them. Eur J Immunol 1984, 14:859-864.
77. Heyman B Regulation of antibody responses via antibodies, complement, and Fc receptors. Ann Rev Immunol 2000, 18:709-737.
78. Cyster JG B cell follicles and antigen encounters of the third kind. Nat Immunol 2010, 11:989-996.
79. Phan TG, Grigorova I, Okada T, Cyster JG Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol 2007, 8:992-1000.
80. Montefiori DC Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Sem Immunopathol 1997, 18:371-390.
81. Kacani L, Prodinger WM, Sprinzl GM, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 2000, 74:7997-8002.
82. Subbramanian RA, Xu J, Toma E, et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol 2002, 40:2141-2146.
83. Horakova E, Gasser O, Sadallah S, et al. Complement mediates the binding of HIV to erythrocytes. J Immunol 2004, 173:4236-4241.
84. Huber G, Banki Z, Lengauer S, Stoiber H Emerging role for complement in HIV infection. Curr Opin HIV AIDS 2011, 6:419-426.
85. Willey S, Aasa-Chapman MM, O'Farrell S, et al. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology 2011, 8:16.
86. Hess C, Klimkait T, Schlapbach L, et al. Association of a pool of HIV-1 with erthrocytes in vivo: cohort study. Lancet 2002, 359:2230-2234.
87. Stoiber H Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?. Curr Opin HIV AIDS 2009, 4:394-399.
88. Banki Z, Wilflingseder D, Ammann CG, et al. Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol 2006, 177:3469-3476.
89. Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000, 192:637-646.
90. Ho J, Moir S, Kulik L, et al. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J Immunol 2007, 178:6968-6974.
91. Thieblemont N, Haeffner-Cavaillon N, Ledur A, et al. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993, 92:106-113.
92. Bajtay Z, Speth C, Erdei A, Dierich MP Productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). J Immunol 2004, 173:4775-4778.
93. Bouhlal H, Chomont N, Requena M, et al. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007, 178:1086-1095.
94. Joling P, Bakker LJ, Van Strijp JAG, et al. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 1993, 150:1065-1073.
95. Bergtold A, Desai DD, Gavhane A, Clynes R Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 2005, 23:503-514.
96. Schreiber AD, Frank MM Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement fixing sites. J Clin Invest 1972, 51:575-582.
97. Schreiber AD, Frank MM Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972, 51:583-589.
98. Atkinson JP, Frank MM Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974, 54:339-348.
99. Atkinson JP, Frank MM Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. Blood 1974, 44:629-637.
100. Atkinson JP, Schreiber AD, Frank MM Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. J Clin Invest 1973, 52:1509-1517.
101. Hinglais N, Kazatchkine MD, Mandet C, Appay M, Bariety J Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. Lab Invest 1989, 61:509-514.
102. da Silveira SA, Kikuchi S, Fossati-Jimack L, et al. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med 2002, 195:665-672.
103. Newman SL, Johnson RB Role of binding through C3b and IgG in polymorphonuclear neutrophil function: studies with trypsin-generated C3b. J Immunol 1979, 123:1839-1846.
104. Brown EJ, Bohnsack JF, Gresham HD Mechanism of inhibition of immunoglobulin G-mediated phagocytosis by monoclonal antibodies that recognize the Mac-1 antigen. J Clin Invest 1988, 81:365-375.
105. Zhou M, Todd RF, van de Winkel JGJ, Petty HR Cocapping of the leukoadhesin molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fcγ Receptor III on human neutrophils. J Immunol 1993, 150:3030-3041.
106. Zhou MJ, Brown EJ CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and FcγRIII cooperate in generation of a neutrophil respiratory burst: requirement for FcγRIII and tyrosine phosphorylation. J Cell Biol 1994, 125:1407-1416.
107. Bouhlal H, Galon J, Kazatchkine M, et al. Soluble CD16 inhibits CR3(CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol 2000, 166:3377-3383.
108. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology 1999, 42:61-74.
109. van Spriel AB, Leusen JHW, van Egmond M, et al. Mac-1 (CD11b/CD18) is essential for Fc receptor mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 2001, 97:2478-2486.
110. van Spriel AB, van Ojik HH, Bakker A, Jansen MJH, van de Winkel JGJ Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003, 101:253-258.
111. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008, 181:822-832.
112. Beum PV, Lindorfer MA, Hall BE, et al. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer. J Immunol Methods 2006, 317:90-99.
113. Boross P, Jansen JHM, de Haij S, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011, 96:1822-1830.
114. Lindorfer MA, Wiestner A, Zent CS, Taylor RP Monoclonal antibody (mAb)-based cancer therapy: is it time to reevaluate dosing strategies?. OncoImmunology. 2012.
115. Imai M, Ohta R, Varela JC, Song H, Tomlinson S Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Canc Res 2007, 67:9535-9541.
116. Elvington M, Huan Y, Morgan BP, et al. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012.
117. Parker CJ The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol 2007, 35:523-533.
118. Walport MJ Complement and systemic lupus erythematosus. Arthritis Res 2002, 4:S279-S293.
119. Köhl J, Gessner JE On the role of complement and Fcγ-receptors in the Arthus reaction. Mol Immunol 1999, 36:893-903.
120. Sylvestre DL, Ravetch JV Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science 1994, 265:1095-1098.
121. Clynes R, Dumitru C, Ravetch JV Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998, 279:1052-1054.
122. Clynes R, Maizes JS, Guinamard R, et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999, 189:179-185.
123. Nimmerjahn F, Ravetch JV Fc-receptors as regulators of immunity. Adv Immunol 2007, 96:179-203.
124. Ravetch J In vivo veritas: the surprising roles of Fc receptors in immunity. Nat Immunol 2010, 11:183-185.
125. Hopken UE, Lu B, Gerard NP, Gerard C Inpaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J Exp Med 1997, 186:749-756.
126. Heller T, Hennecke M, Baumann U, et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory resonse in immune complex disease and ischemia/reperfusion injury. J Immunol 1999, 163:985-994.
127. Heller T, Gessner JE, Schmidt RE, et al. Cutting edge: Fc receptor type I for IgG macrophages and complement mediate the inflammatory response in immune complex peritonitis. J Immunol 1999, 162:5657-5661.
128. Ji H, Ohmura K, Mahmood U, et al. Arthritis critically dependent on innate immune system players. Immunity 2002, 16:157-168.
129. Baumann U, Chouchakova N, Gewecke B, et al. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex-induced injury of skin and lung. J Immunol 2001, 167:1022-1027.
130. Godau J, Heller T, Hawlisch H, et al. C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol 2004, 173:3437-3445.
131. Kumar V, Ali SR, Konrad S, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006, 116:512-520.
132. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J Clin Invest 2002, 110:1823-1830.
133. Konrad S, Engling L, Schmidt RE, Gessner JE Characterization of the murine IgG Fc receptor III and IIB gene promoters. A single two-nucleotide difference determines their inverse responsiveness to C5a. J Biol Chem 2007, 282:37906-37912.
134. Konrad S, Ali SR, Wiege K, et al. Phosphoinositide 3-kinases γ and δ, linkers of coordinate C5a receptor-Fcγ receptor activation and immune complex-induced inflammation. J Biol Chem 2008, 283:33296-33303.
135. Skokowa J, Ali SR, Felda O, et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G-αi2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005, 174:3041-3050.
136. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006, 12:682-687.
137. Brekke OL, Christiansen D, Fure H, Fung M, Mollnes TE The role of complement C3 opsonization, C5a receptor, and CD14 in E.coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leuk Biol 2007, 81:1404-1413.
138. Kavai M, Szegedi G Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus. Autoimmun Rev 2007, 6:497-502.
139. Fries LF, Mullins WW, Cho KR, Plotz PH, Frank MM Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus. J Immunol 1984, 132:695-700.
140. Yancey KB, O'Shea J, Chused T, et al. Human C5a modulates monocyte Fc and C3 receptor expression. J Immunol 1985, 135:465-470.
141. Salmon JE, Kimberly RP, Gibofsky A, Fotina M Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. J Immunol 1984, 133:2525-2531.
142. Zhang CY, Booth JW Divergent intracellular sorting of FcγRIIA and FcγRIIB2. J Biol Chem 2010, 285:34250-34528.
143. Ukkonen P, Lewis V, Marsh M, Helenius A, Mellman I Transport of macrophage Fc receptors and Fc receptor-bound ligands to lysosomes. J Exp Med 1986, 163:952-971.
144. Taylor RP, Lindorfer MA Drug insight: the mechanism of action of rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheum 2007, 3:86-95.
145. Bowles JA, Weiner GJ CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005, 304:88-99.
146. Davis W, Harrison PT, Hutchinson MJ, Allen JM Two distinct regions of FcγRI initiate separate signalling pathways involved in endocytosis and phagocytosis. EMBO J 1995, 14:432-441.
147. Lovdal T, Andersen E, Brech ABT Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 2000, 113:3255-3266.
148. Ahuja A, Teichmann LL, Wang H, et al. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in lupus. J Immunol 2011, 187:3888-3894.
149. Banda NK, Thurmann JM, Kraus D, et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol 2006, 177:1904-1912.
150. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol 2007, 179:4101-4109.
151. Banda N, Takahashi M, Levitt B, et al. Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol 2010, 185:5598-5606.
152. Banda NK, Hyatt S, Antonioli AH, et al. Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis. J Immunol 2012, 188:1469-1478.